|Bid||3.4800 x 29200|
|Ask||3.5000 x 28000|
|Day's Range||3.3600 - 3.7000|
|52 Week Range||1.1600 - 6.2800|
|Beta (5Y Monthly)||2.24|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||8.67|
SAN DIEGO, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced the publication of the first study to evaluate the utility of optical genome mapping (OGM) in the analysis of repeat expansion disorders. Repeat expansion disorders are a class of disorders that impact approximately 1 in 3,000 people and are caused by expansions of short tandem DNA repeats. Researchers in this study describe how OGM can be adopted as an alternative to Southern blot analysis for the
Image source: The Motley Fool. Bionano Genomics, Inc (NASDAQ: BNGO)Q2 2022 Earnings CallAug 04, 2022, 4:30 p.m. ETContents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: OperatorGood day, and welcome to the Bionano Genomics second quarter 2022 earnings conference call.
Now's a great time to invest in companies with the potential to grow significantly in the long term.